Cargando…

A Description of the Statistical Methods for the Vaccine Impact on Diarrhea in Africa (VIDA) Study

BACKGROUND: Diarrheal diseases remain a health threat to children in low- and middle-income countries. The Vaccine Impact on Diarrhea in Africa (VIDA) study was a 36-month, prospective, matched case-control study designed to estimate the etiology, incidence, and adverse clinical consequences of mode...

Descripción completa

Detalles Bibliográficos
Autores principales: Powell, Helen, Liang, Yuanyuan, Neuzil, Kathleen M, Jamka, Leslie P, Nasrin, Dilruba, Sow, Samba O, Hossain, M Jahangir, Omore, Richard, Kotloff, Karen L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116558/
https://www.ncbi.nlm.nih.gov/pubmed/37074428
http://dx.doi.org/10.1093/cid/ciac968
_version_ 1785028450176729088
author Powell, Helen
Liang, Yuanyuan
Neuzil, Kathleen M
Jamka, Leslie P
Nasrin, Dilruba
Sow, Samba O
Hossain, M Jahangir
Omore, Richard
Kotloff, Karen L
author_facet Powell, Helen
Liang, Yuanyuan
Neuzil, Kathleen M
Jamka, Leslie P
Nasrin, Dilruba
Sow, Samba O
Hossain, M Jahangir
Omore, Richard
Kotloff, Karen L
author_sort Powell, Helen
collection PubMed
description BACKGROUND: Diarrheal diseases remain a health threat to children in low- and middle-income countries. The Vaccine Impact on Diarrhea in Africa (VIDA) study was a 36-month, prospective, matched case-control study designed to estimate the etiology, incidence, and adverse clinical consequences of moderate-to-severe diarrhea (MSD) in children aged 0–59 months. VIDA was conducted following rotavirus vaccine introduction at 3 censused sites in sub-Saharan Africa that participated in the Global Enteric Multicenter Study (GEMS) ∼10 years earlier. We describe the study design and statistical methods of VIDA and where they differ from GEMS. METHODS: We aimed to enroll 8–9 MSD cases every 2 weeks from sentinel health centers in 3 age strata (0–11, 12–23, 24–59 months) and 1 to 3 controls matched by age, sex, date of case enrollment, and village. Clinical, epidemiological, and anthropometric data were collected at enrollment and ∼60 days later. A stool specimen collected at enrollment was analyzed by both conventional methods and quantitative PCR for enteric pathogens. For the matched case-control study, we estimated the population-based, pathogen-specific attributable fraction (AF) and attributable incidence adjusted for age, site, and other pathogens, and identified episodes attributable to a specific pathogen for additional analyses. A prospective cohort study nested within the original matched case-control study allowed assessment of (1) the association between potential risk factors and outcomes other than MSD status and (2) the impact of MSD on linear growth. CONCLUSIONS: GEMS and VIDA together comprise the largest and most comprehensive assessment of MSD conducted to date in sub-Saharan Africa populations at highest risk for morbidity and mortality from diarrhea. The statistical methods used in VIDA have endeavored to maximize the use of available data to produce more robust estimates of the pathogen-specific disease burden that might be prevented by effective interventions.
format Online
Article
Text
id pubmed-10116558
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-101165582023-04-21 A Description of the Statistical Methods for the Vaccine Impact on Diarrhea in Africa (VIDA) Study Powell, Helen Liang, Yuanyuan Neuzil, Kathleen M Jamka, Leslie P Nasrin, Dilruba Sow, Samba O Hossain, M Jahangir Omore, Richard Kotloff, Karen L Clin Infect Dis VIDA Supplement BACKGROUND: Diarrheal diseases remain a health threat to children in low- and middle-income countries. The Vaccine Impact on Diarrhea in Africa (VIDA) study was a 36-month, prospective, matched case-control study designed to estimate the etiology, incidence, and adverse clinical consequences of moderate-to-severe diarrhea (MSD) in children aged 0–59 months. VIDA was conducted following rotavirus vaccine introduction at 3 censused sites in sub-Saharan Africa that participated in the Global Enteric Multicenter Study (GEMS) ∼10 years earlier. We describe the study design and statistical methods of VIDA and where they differ from GEMS. METHODS: We aimed to enroll 8–9 MSD cases every 2 weeks from sentinel health centers in 3 age strata (0–11, 12–23, 24–59 months) and 1 to 3 controls matched by age, sex, date of case enrollment, and village. Clinical, epidemiological, and anthropometric data were collected at enrollment and ∼60 days later. A stool specimen collected at enrollment was analyzed by both conventional methods and quantitative PCR for enteric pathogens. For the matched case-control study, we estimated the population-based, pathogen-specific attributable fraction (AF) and attributable incidence adjusted for age, site, and other pathogens, and identified episodes attributable to a specific pathogen for additional analyses. A prospective cohort study nested within the original matched case-control study allowed assessment of (1) the association between potential risk factors and outcomes other than MSD status and (2) the impact of MSD on linear growth. CONCLUSIONS: GEMS and VIDA together comprise the largest and most comprehensive assessment of MSD conducted to date in sub-Saharan Africa populations at highest risk for morbidity and mortality from diarrhea. The statistical methods used in VIDA have endeavored to maximize the use of available data to produce more robust estimates of the pathogen-specific disease burden that might be prevented by effective interventions. Oxford University Press 2023-04-19 /pmc/articles/PMC10116558/ /pubmed/37074428 http://dx.doi.org/10.1093/cid/ciac968 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle VIDA Supplement
Powell, Helen
Liang, Yuanyuan
Neuzil, Kathleen M
Jamka, Leslie P
Nasrin, Dilruba
Sow, Samba O
Hossain, M Jahangir
Omore, Richard
Kotloff, Karen L
A Description of the Statistical Methods for the Vaccine Impact on Diarrhea in Africa (VIDA) Study
title A Description of the Statistical Methods for the Vaccine Impact on Diarrhea in Africa (VIDA) Study
title_full A Description of the Statistical Methods for the Vaccine Impact on Diarrhea in Africa (VIDA) Study
title_fullStr A Description of the Statistical Methods for the Vaccine Impact on Diarrhea in Africa (VIDA) Study
title_full_unstemmed A Description of the Statistical Methods for the Vaccine Impact on Diarrhea in Africa (VIDA) Study
title_short A Description of the Statistical Methods for the Vaccine Impact on Diarrhea in Africa (VIDA) Study
title_sort description of the statistical methods for the vaccine impact on diarrhea in africa (vida) study
topic VIDA Supplement
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116558/
https://www.ncbi.nlm.nih.gov/pubmed/37074428
http://dx.doi.org/10.1093/cid/ciac968
work_keys_str_mv AT powellhelen adescriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy
AT liangyuanyuan adescriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy
AT neuzilkathleenm adescriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy
AT jamkalesliep adescriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy
AT nasrindilruba adescriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy
AT sowsambao adescriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy
AT hossainmjahangir adescriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy
AT omorerichard adescriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy
AT kotloffkarenl adescriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy
AT powellhelen descriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy
AT liangyuanyuan descriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy
AT neuzilkathleenm descriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy
AT jamkalesliep descriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy
AT nasrindilruba descriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy
AT sowsambao descriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy
AT hossainmjahangir descriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy
AT omorerichard descriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy
AT kotloffkarenl descriptionofthestatisticalmethodsforthevaccineimpactondiarrheainafricavidastudy